Biotech · Private company · Rockville, MD, US
Supernus Pharmaceuticals, Inc.
SEC CIK 0001356576
Track this companyFree. Adds Supernus Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials258 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- SAGE-547Phase 3 · Super-Refractory Status EpilepticusClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-547 60 μg/kg/hPhase 3 · Postpartum DepressionClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-547 90 μg/kg/hPhase 3 · Postpartum DepressionClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-718Phase 3 · Huntington's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SPN-812Phase 3 · Attention-Deficit/Hyperactivity DisorderClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-547Phase 2 · Severe Postpartum DepressionClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-547Phase 2 · Postpartum DepressionClinicalTrials.gov · fetched Nov 12, 2026
- SPN-810Phase 2 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
- SPN-817Phase 2 · Focal Onset SeizuresClinicalTrials.gov · fetched Nov 12, 2026
- SPN-817Phase 2 · EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- SPN-821 2400 mgPhase 2 · Major Depressive Disorder (MDD)ClinicalTrials.gov · fetched Nov 12, 2026
- KetaminePhase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-718Phase 1 · Huntington DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-718Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- SAGE-904Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- 100mg SPN-812Attention-Deficit/Hyperactivity DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Observational studyParkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SPN-538Migraine DisordersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderPHASE2 · RECRUITING · started Jan 19, 2026ClinicalTrials.gov NCT07226661 · fetched Nov 12, 2026
- SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresPHASE2 · ENROLLING_BY_INVITATION · started Jul 30, 2025ClinicalTrials.gov NCT07141329 · fetched Nov 12, 2026
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:RECRUITING · started Mar 31, 2025ClinicalTrials.gov NCT07219927 · fetched Nov 12, 2026
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresPHASE2 · RECRUITING · started Dec 30, 2024ClinicalTrials.gov NCT06798896 · fetched Nov 12, 2026
- Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood SymptomsPHASE4 · COMPLETED · started Mar 25, 2024ClinicalTrials.gov NCT06185985 · fetched Nov 12, 2026
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDPHASE4 · RECRUITING · started Mar 19, 2024ClinicalTrials.gov NCT04781140 · fetched Nov 12, 2026
- Open-Label of SPN-820 in Adults With Major Depressive DisorderPHASE2 · COMPLETED · started Feb 15, 2024ClinicalTrials.gov NCT06235905 · fetched Nov 12, 2026
- Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyPHASE2 · RECRUITING · started Feb 7, 2023ClinicalTrials.gov NCT05518578 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseasePHASE3 · TERMINATED · started Dec 14, 2022ClinicalTrials.gov NCT05655520 · fetched Nov 12, 2026
- Phase 2 Study of NV-5138 in Adults With Treatment Resistant DepressionPHASE2 · COMPLETED · started Jan 18, 2022ClinicalTrials.gov NCT05066672 · fetched Nov 12, 2026
- Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy ParticipantsPHASE1 · COMPLETED · started Sep 21, 2021ClinicalTrials.gov NCT05049343 · fetched Nov 12, 2026
- Therapy for Migraine Prevention in Children 6-11 Years of AgePHASE4 · TERMINATED · started Jul 14, 2020ClinicalTrials.gov NCT04050293 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BPHASE1 · COMPLETED · started Feb 28, 2019ClinicalTrials.gov NCT03787758 · fetched Nov 12, 2026
- A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy SubjectsPHASE1 · COMPLETED · started Dec 27, 2018ClinicalTrials.gov NCT03844906 · fetched Nov 12, 2026
- A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsPHASE1 · COMPLETED · started Nov 12, 2018ClinicalTrials.gov NCT03770780 · fetched Nov 12, 2026
- A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsPHASE1 · COMPLETED · started Sep 24, 2018ClinicalTrials.gov NCT03771586 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)PHASE3 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02942004 · fetched Nov 12, 2026
- A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)PHASE3 · COMPLETED · started Jul 1, 2016ClinicalTrials.gov NCT02942017 · fetched Nov 12, 2026
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)PHASE3 · ACTIVE_NOT_RECRUITING · started Feb 2, 2016ClinicalTrials.gov NCT02736656 · fetched Nov 12, 2026
- A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionPHASE2 · COMPLETED · started Dec 15, 2015ClinicalTrials.gov NCT02614547 · fetched Nov 12, 2026
- A Study With SAGE-547 for Super-Refractory Status EpilepticusPHASE3 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02477618 · fetched Nov 12, 2026
- Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionPHASE2 · COMPLETED · started Jan 7, 2015ClinicalTrials.gov NCT02285504 · fetched Nov 12, 2026
- Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status EpilepticusPHASE1_PHASE2 · COMPLETED · started Mar 21, 2014ClinicalTrials.gov NCT02052739 · fetched Nov 12, 2026
- National Pregnancy Registry for Psychiatric MedicationsRECRUITING · started Nov 1, 2008ClinicalTrials.gov NCT01246765 · fetched Nov 12, 2026
- Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsPHASE2 · COMPLETED · started Oct 21, 2008ClinicalTrials.gov NCT00626236 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 26, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026